Regeneron Pharmaceuticals Announced New Analyses Of Eylea HD (Aflibercept) Injection 8 Mg And Eylea Injection 2 Mg Will Be Presented At The Annual Meeting Of The European Society Of Retina Specialists

Author: Benzinga Newsdesk | September 11, 2024 07:04am

Among the presentation highlights are several new post-hoc analyses of the pivotal PULSAR trial for EYLEA HD in wet age-related macular degeneration (wAMD). These include first-time oral presentations of:

• An analysis applying disease activity criteria from the faricimab Phase 3 wAMD trials to EYLEA HD to evaluate the impact on the decision for extended dosing intervals.
• An analysis evaluating the impact of EYLEA HD on sustained fluid control throughout two years of treatment as measured by central retinal thickness and best-corrected visual acuity.
• The safety of EYLEA HD from an analysis evaluating intraocular pressure outcomes through week 96.

Posted In: REGN